A collection of stock notes from around the web.
April 15, 2009
6.50 Price Target on ZymoGenetics
Zacks has a
$6.50 price target
on ZymoGenetics, sighting the recent approval of
of rhThrombin by the FDA. That is slightly more than double the current price.
Post a Comment
Post Comments (Atom)